Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these recent advances, the success of CD3 bsAbs in solid cancer has been hampered by hurdles like...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1548446/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861107425542144 |
|---|---|
| author | Katy Lloyd Jim Middelburg Vitalijs Ovcinnikovs Nora Pencheva Kristel Kemper Thorbald van Hall |
| author_facet | Katy Lloyd Jim Middelburg Vitalijs Ovcinnikovs Nora Pencheva Kristel Kemper Thorbald van Hall |
| author_sort | Katy Lloyd |
| collection | DOAJ |
| description | CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these recent advances, the success of CD3 bsAbs in solid cancer has been hampered by hurdles like limited intratumoral T cell numbers, immunosuppressive tumor microenvironments (TME), and poor memory T-cell induction. Furthermore, tumor surface antigen selection for an optimal therapeutic window and acceptable collateral damage to normal tissues is challenging. In this review, we discuss recent research investigating combination approaches aimed at improving CD3 bsAb efficacy in solid cancer. |
| format | Article |
| id | doaj-art-72579e3c27544d5f9eda517d5a55eabb |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-72579e3c27544d5f9eda517d5a55eabb2025-02-10T05:16:00ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.15484461548446Improving CD3 bispecific antibody therapy in solid tumors using combination strategiesKaty Lloyd0Jim Middelburg1Vitalijs Ovcinnikovs2Nora Pencheva3Kristel Kemper4Thorbald van Hall5Genmab B.V., Utrecht, NetherlandsDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, NetherlandsGenmab B.V., Utrecht, NetherlandsGenmab B.V., Utrecht, NetherlandsGenmab B.V., Utrecht, NetherlandsDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, NetherlandsCD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despite these recent advances, the success of CD3 bsAbs in solid cancer has been hampered by hurdles like limited intratumoral T cell numbers, immunosuppressive tumor microenvironments (TME), and poor memory T-cell induction. Furthermore, tumor surface antigen selection for an optimal therapeutic window and acceptable collateral damage to normal tissues is challenging. In this review, we discuss recent research investigating combination approaches aimed at improving CD3 bsAb efficacy in solid cancer.https://www.frontiersin.org/articles/10.3389/fonc.2025.1548446/fullantibodyCD3bispecific Abcancervaccination |
| spellingShingle | Katy Lloyd Jim Middelburg Vitalijs Ovcinnikovs Nora Pencheva Kristel Kemper Thorbald van Hall Improving CD3 bispecific antibody therapy in solid tumors using combination strategies Frontiers in Oncology antibody CD3 bispecific Ab cancer vaccination |
| title | Improving CD3 bispecific antibody therapy in solid tumors using combination strategies |
| title_full | Improving CD3 bispecific antibody therapy in solid tumors using combination strategies |
| title_fullStr | Improving CD3 bispecific antibody therapy in solid tumors using combination strategies |
| title_full_unstemmed | Improving CD3 bispecific antibody therapy in solid tumors using combination strategies |
| title_short | Improving CD3 bispecific antibody therapy in solid tumors using combination strategies |
| title_sort | improving cd3 bispecific antibody therapy in solid tumors using combination strategies |
| topic | antibody CD3 bispecific Ab cancer vaccination |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1548446/full |
| work_keys_str_mv | AT katylloyd improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies AT jimmiddelburg improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies AT vitalijsovcinnikovs improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies AT norapencheva improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies AT kristelkemper improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies AT thorbaldvanhall improvingcd3bispecificantibodytherapyinsolidtumorsusingcombinationstrategies |